Market Place
Sourcing Support
Lisata Therapeutics Wins BioTech Breakthrough Award 2024
19 Nov 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Report Q3 2024 Financials & Updates Nov 12
06 Nov 2024 //
GLOBENEWSWIRE
Lisata & Valo Announce Preclinical Research Collaboration
06 Nov 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Attend Industry & Investor Events in Nov
31 Oct 2024 //
GLOBENEWSWIRE
Lisata Signs Research Agreement on Certepetide for Endometriosis
28 Oct 2024 //
#N/A
Lisata To Join October 2024 Industry And Investor Events
03 Oct 2024 //
GLOBENEWSWIRE
LisataAnnounces Treatment First Patient in BOLSTER Trial Cohort
17 Sep 2024 //
GLOBENEWSWIRE
Lisata Therapeutics To Participate In September Events
09 Sep 2024 //
GLOBENEWSWIRE
Lisata`s Certepetide Granted FDA Orphan Drug Designation
05 Sep 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Q2 2024 Results And Business Update
12 Aug 2024 //
GLOBENEWSWIRE
Lisata Therapeutics To Report Q2 2024 Results On August 12
05 Aug 2024 //
GLOBENEWSWIRE
Haystack And Lisata Partner On Pancreatic Cancer Therapy Evaluation
18 Jul 2024 //
GLOBENEWSWIRE
Lisata Completes Enrollment In Certepetide Cholangiocarcinoma Trial
16 Jul 2024 //
GLOBENEWSWIRE
Lisata`s Certepetide Shows Promise For Intrahepatic Cholangiocarcinoma
10 Jul 2024 //
GLOBENEWSWIRE
Lisata Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
13 Jun 2024 //
GLOBENEWSWIRE
Lisata Therapeutics: Participating In June 2024 Industry, Investor Events
28 May 2024 //
GLOBENEWSWIRE
Lisata Receives EMA Paediatric Waiver For Certepetide In Pancreatic Cancer
20 May 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Lisata to Participate in Upcoming May 2024 Industry and Investor Events
08 May 2024 //
GLOBENEWSWIRE
Lisata Q1 2024 Results, Business Update On May 9
02 May 2024 //
GLOBENEWSWIRE
Lisata and Qilu Treat First Patient in LSTA1 Pancreatic Cancer Trial
23 Apr 2024 //
GLOBENEWSWIRE
Lisata Therapeutics Announces FDA Orphan Drug Designation Granted to LSTA1
09 Apr 2024 //
GLOBENEWSWIRE
Lisata to Participate in Upcoming April 2024 Industry and Investor Events
03 Apr 2024 //
GLOBENEWSWIRE
Lisata clinches rare disease status for osteosarcoma drug
22 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Lisata Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1
21 Mar 2024 //
GLOBENEWSWIRE
Lisata Reports Full Year 2023 Financial Results and Provides Business Update
29 Feb 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Host Year-End 2023 Conference Call
22 Feb 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at BIO CEO & Investor Conference
20 Feb 2024 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
18 Jan 2024 //
GLOBENEWSWIRE
Lisata Announces First Patient Treated in the Phase 2a Trial of LSTA1
17 Jan 2024 //
GLOBENEWSWIRE
Lisata Announces Publication of Case Report on Patient Treated with LSTA1
04 Jan 2024 //
GLOBENEWSWIRE
Lisata Announces Completion of Enrollment in Phase 2b Trial of LSTA1
12 Dec 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at NobleCon19 Investor Conference
28 Nov 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
09 Nov 2023 //
GLOBENEWSWIRE
Lisata Reports Third Quarter 2023 Financial Results and Provides Business Update
02 Nov 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference
26 Oct 2023 //
GLOBENEWSWIRE
Lisata Announces First Patient Treated in Cohort of the BOLSTER Trial of LSTA1
24 Oct 2023 //
GLOBENEWSWIRE
Lisata Announces EMA Has Granted LSTA1 Orphan Drug Designation
17 Oct 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
28 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in InfoSec World 2023
20 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces First Patient Treated in BOLSTER Trial of LSTA1
12 Sep 2023 //
GLOBENEWSWIRE
Lisata Announces Outcome of Futility Analysis for its Phase 2b Trial of LSTA1
06 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
05 Sep 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Lisata Announces U.S. FDA Orphan Drug Designation Granted to LSTA1
08 Aug 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Report Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Lisata Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
11 Jul 2023 //
GLOBENEWSWIRE
Lisata to Present at the GCFF Innovation and Healthcare Virtual Conference
12 Jun 2023 //
GLOBENEWSWIRE
Lisata Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
24 May 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Host First Quarter 2023 FYR Conference Call
02 May 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Announces Participation in Upcoming Conferences in May
27 Apr 2023 //
GLOBENEWSWIRE
Lisata Therapeutics Receives $2.2 M of Non-Dilutive Capital Through New Jersey
20 Apr 2023 //
GLOBENEWSWIRE
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
19 Apr 2023 //
GLOBENEWSWIRE
Lisata & WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1
18 Apr 2023 //
GLOBENEWSWIRE
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger
15 Sep 2022 //
GLOBENEWSWIRE
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata
14 Sep 2022 //
GLOBENEWSWIRE
Caladrius Merger Partner, Cend, Announces Collaboration Agreement with Roche
10 Aug 2022 //
GLOBENEWSWIRE
Caladrius Bio Completes Enrollment in PIb of CLBS201 in Diabetic Kidney Disease
02 Aug 2022 //
GLOBENEWSWIRE
Caladrius Bio to Host Second Quarter 2022 Financial Results Conference Call
28 Jul 2022 //
GLOBENEWSWIRE
